p53 in the Cytoplasm A Question of Overkill? by Baptiste, Nicole & Prives, Carol
Previews
487
the PP region of p53 is critical for p53s ability to inducep53 in the Cytoplasm:
apoptosis, whether it occurs by transcription-depen-A Question of Overkill? dent or -independent mechanisms.
Now the Green laboratory presents new data that ex-
tend their previous findings in unexpected ways (Chipuk
et al., 2004). UV-treated E1A- and Ras-transformed wild-The tumor suppressor p53 regulates cellular responses
type (but not bax/ or p53/) mouse embryonic fibro-to stress by serving in the nucleus to regulate tran-
blasts (MEFs) undergo cell death even when they arescription of genes involved in processes including cell
treated with the nuclear import inhibitor wheat germcycle arrest, DNA repair, and apoptosis. Nevertheless,
agglutinin (WGA), which causes p53 to accumulate ex-recent papers show that p53 may have a separate
clusively in the cytoplasm. Notably, while MEFs express-cytoplasmic role in directly regulating the Bax-depen-
ing the murine p53 mutant p53Q25/S26 that correspondsdent mitochondrial pathway to cell death.
to human p53Q22/S23 do not die upon UV irradiation, the
same cells when treated with WGA undergo apoptosisThe p53 tumor suppressor protein is a well-character-
even without a DNA damage signal. Thus, transcription-ized transcription factor that is responsible for the direct
ally impaired p53 cannot induce apoptosis unless local-activation of numerous genes involved in many cellular
ized to the cytoplasm. These results imply that regula-functions including apoptosis (Shen and White, 2001;
tion of cytoplasmic wild-type p53 levels by Mdm2 mayVousden and Lu, 2002; Vogelstein et al., 2000). In this
be important in controlling the ability of p53 to cause cellcapacity, p53 functions indisputably in the nucleus,
death. Indeed, when physiological quantities of purifiedwhere it associates with chromatin and chromatin
wild-type p53 from UV-treated cells (or p53Q25/S26) arebound factors. In fact, numerous transcriptional targets
microinjected into cycloheximide- or WGA-treated HeLaof p53 (e.g., Bax) regulate the mitochondrial arm of the
cells, cytochrome c release occurs, while microinjectedprocess of apoptosis. It has therefore been a mystery
PP p53 does not elicit this outcome. Further, Chipukhow p53 causes apoptosis under conditions that clearly
et al. showed that purified wild-type p53 protein but notexclude its function as a transcription factor. Two inter-
PP p53 causes cytochrome c release from isolatedesting studies from D. Green and colleagues (Chipuk et
mitochondria in a manner that requires added Bax pro-al., 2003, 2004) have added new insight into the nonca-
tein. Bax oligomerization is an obligate step in activatingnonical role for p53 in apoptosis.
Bax to assist in mitochondrial outer membrane permea-Earlier studies supporting a nontraditional role of p53
bilization (MOMP) (reviewed in Adams, 2003). Indeed,in cell death showed that p53 can initiate apoptosis in
Bax works with Bid, wild-type p53, or p53Q25/S26 to causecells in which transcription and translation are inhibited
release of labeled dextrans from lipid vesicles, an assayand that transcriptionally impaired mutant forms of p53
that mimics MOMP. More strikingly, purified p53 orare fully capable of causing apoptosis in some cell-
p53Q25/S26 can cause monomeric Bax protein to formbased assays. Chipuk et al. (2003) have first confirmed
oligomers under these conditions, while PP p53 failsprevious studies that ectopic expression of p53 mutants
to do this. Hence, p53 with an intact proline-rich region
including p531-102 lacking the DNA binding domain,
can engage the mitochondrial death pathway through
p53Q22/S23 mutated in the transactivation and Mdm2 inter-
Bax oligomerization by inducing MOMP and cytochrome
action regions, or p53NLS without a nuclear localization
c release.
signal could still induce apoptosis. They also showed These studies are interesting when considered to-
that transcription-independent p53-mediated apoptosis gether with previous reports (Mihara et al., 2003; Dumont
can be inhibited by overexpression of the survival pro- et al., 2003), which showed that p53 can localize to
tein Bcl-XL, thus demonstrating a crucial role of the mitochondria and induce the release of mitochondrial
Bcl2 family of proteins in the regulation of this process. cytochrome c. Mihara et al. reported that p53 can bind
Previously, Bykov et al. (2002) identified a small mole- Bcl-XL and that a region in the central conserved p53
cule (PRIMA-1) that induces p53-dependent apoptosis core domain (residues 239–248) is required for this inter-
in cells expressing tumor-derived mutant forms of p53. action, while Dumont et al. showed that a common p53
Interestingly, Chipuk et al. found that PRIMA-1 activates polymorphic variant R72 (instead of P72) increases nu-
apoptosis in cells expressing either wild-type p53 or the clear export, mitochondrial localization, and apoptosis.
tumor-derived p53 mutants, M246I and R273H, in the Extending the findings of Mihara et al., the Green labora-
absence of new protein synthesis. Previous findings tory also reported that wild-type p53 can associate with
(Baptiste et al., 2002 and references therein) that the exogenous and endogenous Bcl-XL while again PP
p53 polyproline domain (PP domain) spanning residues p53 cannot do so. Importantly, Chipuk et al. showed
62–91 is necessary for p53 to cause apoptosis and facili- that the p53/Bcl-XL interaction is so strong that a vast
tate p53 transactivation of proapoptotic genes were ex- excess of Bid (or Bax) is required to displace pre-bound
tended when Chipuk et al. showed that PRIMA-1 does p53 from Bcl-XL.
not activate transcription-independent apoptosis in Taken together, these groups have made a number of
cells expressing a p53 variant (PP p53) that lacks the observations that provide insight into the transcription-
PP domain. Furthermore, cytoplasts (nuclei-free cells) independent functions of p53 in promoting apoptosis
from H1299 human lung carcinoma cells stably express- (see Figure 1B). First, excluding p53 from the nucleus
ing ectopic wild-type p53, but not from H1299 cells causes apoptosis (if levels of p53 can reach a certain
expressing PP p53, undergo Bax translocation, cyto- threshold). Second, p53 binds Bcl-XL with a higher affin-
chrome c release, and caspase-dependent phosphati- ity than some BH3-only proteins such as Bid, and such
binding can release Bid or other BH3-only proteins fromdylserine externalization. These new findings show that
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Figure 1. Nuclear and Cytoplasmic Roles of p53 in Apoptosis
(A) Domains of p53 protein including transactivation (TA), polyproline (PP), central core-specific DNA binding region, tetramerization (Tet), and
basic () regions.
(B) A model depicting the transcription-dependent and -independent roles of p53 during apoptosis. Stress signals stabilize nuclear p53, which
binds to and activates transcription of proapoptotic p53 target genes and triggers apoptosis. Cytoplasmically localized p53 can either directly
induce Bax oligomerization or liberate proapoptotic BH3-only proteins bound to Bcl2/Bcl-XL at the mitochondria. The released BH3-only
proteins can then activate Bax oligomerization and thereby cause cytochrome c release leading to apoptosis.
Bcl-XL/BH3 protein complexes. Third, p53 protein can Whatever the differences noted in these studies, the
common findings among these groups are fascinatingunder some circumstances localize to and cause cyto-
chrome c release from purified mitochondria. Fourth, and provide for the first time new insight into proapo-
ptotic functions of p53 that are completely independentthe p53 PP domain (which harbors amino acid 72) plays
an important role in promoting transcription-indepen- of its canonical role as a transcription factor. Some
questions can be posed that may now be approached.dent apoptosis.
Nevertheless, there are also some intriguing discrep- What is the role of the p53 PP domain in promoting
apoptosis? Elucidation of the structure of the p53/Bcl-ancies among the findings of these different groups. For
one, it is not clear whether the PP domain or the region XL complex may help solve the mystery. How can we
unify the different roles of p53 in apoptosis? Perhapsidentified by Mihara et al. work together or separately in
allowing p53 to promote apoptosis. Since p53 residues transactivation by nuclear p53 is required in order to
raise the levels of proapoptotic proteins required for1–102 can cause apoptosis, residues 239–248 are not
absolutely essential for this activity of p53, and whether its cytoplasmic function. Alternately, the cytoplasmic/
mitochondrial role of p53 may occur only under special-they affect the function of the PP domain or play an
independent role remains to be determined. For another, ized circumstances, and transactivation is the major
function of p53 for apoptosis. Thus, while we can nowChipuk et al. showed that purified p53 cannot induce
mitochondrial cytochrome c release without added Bax be confident that p53 can function to promote apoptosis
in the cytoplasm, when and in what sorts of cells doesprotein, while Mihara et al. found p53 can do this in the
absence of Bax. Whether the source of mitochondria this “alter ego” form of p53 occur? Finally, and perhaps
most importantly, does transcription-independent apo-used (perhaps differing in the amount of associated Bak)
or whether the concentrations of p53 used in the respec- ptosis play a role in the tumor suppressor function of
p53? Hopefully answers to these questions will betive assays are responsible for these discrepancies
needs to be further explored. gained in future studies.
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